Invitrogen launches new business unit
The company’s new business unit will be responsible for integrating relevant technologies including Dynal magnetic beads for cell isolation, Gibco cell expansion media and Molecular Probes cell characterization
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.